|Phase I: |
Primary objective: To determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of oxaliplatin in combination with fludarabine and cytarabine.
Primary objective: To assess the objective response rates, including complete and partial response rates, and to define the safety and toxicity profile.
(a) To determine the duration of response, disease-free survival, and overall survival and
(b) To determine the pharmacokinetics and pharmacodynamics of oxaliplatin administered alone and following infusion of fludarabine and cytarabine.